⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NRIX News
Nurix Therapeutics, Inc. Common stock
Form 8-K
sec.gov
NRIX
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
NRIX
Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia
globenewswire.com
NRIX
Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences
globenewswire.com
NRIX
GILD
Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer
globenewswire.com
NRIX
Nurix Therapeutics to Participate in Upcoming September Investor Conferences
globenewswire.com
NRIX
Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer
globenewswire.com
NRIX
Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader
globenewswire.com
NRIX
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
globenewswire.com
NRIX
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
globenewswire.com
NRIX